BEGIN:VCALENDAR PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN VERSION:2.0 BEGIN:VEVENT DESCRIPTION:25th Pharmacovigilance 2021 \n\n“Latest developments in pharma covigilance\, drug safety &\; risk management”\n\n22nd - 23rd Septembe r 2021\, Virtual Conference (Time Zone - EST)\n\nAfter the successful jou rney of a series of 24 Pharmacovigilance conferences\, Virtue Insight is proud to announce its 25th Pharmacovigilance 2021. We have been deliverin g the conference through close collaboration with the industry leaders fo r more than a decade. For the 2021 edition\, the agenda includes a host o f new and exciting features. Take a chance and make it count by attending this conference to network with your peers\, exchange expertise and expe riences\, and arm yourself with the latest information to take your depar tment to the next level.\n\nDELEGATE REGISTRATION:\n\nEmail - kavitha@vir tueinsight.co.in or TEL: +44-20 3509 3779\n\nPlease note that this is a P AID event and NOT A FREE event (no complimentary passes available). Any i nvite\, email or tickets issued mentioning it as a free pass or free tick et to this event through any third party site will strictly not be accept ed by the organizer.\n\nEARLY BIRD PRICE (Valid Till 16th August 2021 - N ot Valid for UK based attendees):\n\n1 Delegate @ £399 \n\n3 Delegates @ £999\n\nEARLY BIRD PRICE (Valid Till 16th August 2021 – For UK based atte ndees):\n\n1 Delegate @ £399+VAT\n\n3 Delegates @ £999+VAT\n\nSTANDARD PR ICE (Valid From 17th August 2021 - Not Valid for UK based attendees)\n\n1 Delegate @ £599\n\n3 Delegates @ £1299\n\nSTANDARD PRICE (Valid From 17t h August 2021 - For UK based attendees)\n\n1 Delegate @ £599+VAT\n\n3 Del egates @ £1299+VAT\n\nConference Sponsor\, Exhibition Stall &\; Paid S peaker Slot - Please email your interest and queries to kavitha@virtueins ight.co.in  \;\n\nKEY SPEAKERS:\n\n\nMIRZA I. RAHMAN\, Senior VP & \; Chief Global PV Officer\, Otsuka Pharmaceutical Development &\; Com mercialization\nJULIE GIROD\, Vice President\, Global Head of Case Manage ment &\; Medical Evaluation\, Sanofi-Aventis\nCARMIT STRAUSS\, Global Safety Director (Benefit Risk Management Officer)\, Amgen\nWILLIAM WANG\, Executive Director\, Clinical Safety Statistics\, Merck\nJUDY LI\, Senio r Director\, Biostatistics Lead\, San Diego Site\, Bristol-Myers Squibb\n MELVIN MUNSAKA\, Senior Director\, Head Safety Statistics\, Abbvie\nARVIN D BELLUR\, Associate Vice President\, Sanofi\nROSALINA DOMIN\, Senior Dir ector\, QA and Deviation Management Head PV Quality\, Sanofi\nKHAUDEJA BA NO\, Executive Medical Director\, Combination Product Safety Head\, Amgen \nSHAUN COMFORT\, Associate Director and Senior Safety Science Leader\, R oche - Genentech\nGIGI ATALLA\, Vice President\, Head of Global Drug Safe ty &\; Pharmacovigilance\, Genmab\nMIRCEA CIUCA\, Global Therapeutic A rea Head - Global Clinical Safety &\; PV\, CSL Behring\nMICHAEL GLASER \, Technology Innovation Director\, GSK\nJAYLAXMI NALAWADE\, Associate Di rector\, Pharmacovigilance and REMS\, Lupin\nKAL ELHOREGY\, Director\, Ri sk Evaluation and Mitigation Strategy (REMS) Programs\, Amneal Pharmaceut icals\nMOHAMED ABDILLAHI\, Director\, Risk management Product Lead\, Pfiz er\nDIMITRIS ZAMPATIS\, Scientific Director\, Safety Strategy Lead\, Heal thcare Business of Merck\nTEODORA DOHERTY\, Global Medical Safety (GMS)\, Medical Safety Officer\, Janssen Research &\; Development\nJOHN SOLOM ON\, Head of Pharmacovigilance UK &\; Ireland\, Sanofi\nSUMIT MUNJAL\, Vice President\, Global Patient Safety Evaluation\, Takeda Pharmaceutica ls\nTANJA PETERS\, Head Global Patient Safety Neurology &\; Immunology \, Merck KGaA\nAYSE BAKER\, Vice President of Regulatory Affairs\, Almati ca (Alvogen)\nRAJ BHOGAL\, Senior Director\, R&\;D Audits &\; Inspe ctions\, Jazz Pharmaceuticals\nTEA BABIC\, Director\, PV Audits and Inspe ctions\, Teva Pharmaceuticals\nISRAEL GUTIERREZ\, VP Pharmacovigilance &a mp\; Drug Safety\, Geron Corporation\nOYINKANSOLA ODEBO\, Assistant Direc tor\, Drug Safety Clinical Research\, Supernus Pharmaceuticals\nDEEPA VEN KATARAMAN\, Head of Global Patient Safety and Pharmacovigilance\, Summit Therapeutics\nKATARINA ILIC\, Senior Clinical Pharmacology Medical Leader \, Takeda Pharmaceuticals\nCHETAN SHATAPATHY\, Consultant Medical Advisor \, (QPPV) (Interim)\, Janssen Pharmaceutical\nKISHAN NANDHA\, PVQA Manage r &\; Lead Auditor\, Astellas Pharmaceuticals\nEMMANUEL PHAM\, Former Vice-President Biometry\, IPSEN\nPAVAN BADALE\, Head- PV Process Excellen ce\, Safety case Management\, Novartis\nZULANE MALDONADO-CRUZ\, Senior Dr ug Safety Specialist\, Supernus Pharmaceuticals\nNICOLE BAKER\, CEO\, Bio logit\nARUN TIRUMALAI\, Technical Consultant\, GSK\nMARINA SUVAKOV\, Glo bal Head Safety Surveillance\, Philip Morris\nDEEPA ARORA\, Director\, CL INEXEL Life Science\nSIVA KUMAR BUDDHA\, Global Safety Physician Manager : Product Safety &\; Risk Management\, Viatris\nJIM BUCHANAN\, Preside nt\, Covilance\nHEIDE CUNNING\, US Pharmacovigilance Officer-Safety Servi ces Operations\, Janssen Pharmaceuticals\nPASQUALE FEDELE\, R&\;D Dire ctor\, Blu Pantheon\nBILL ARONSON\, COO\, Artificial Intelligence Researc h Group\nADI BEN-ARI\, Founder &\; CEO\, Applied Blockchain\nKAVYA KAD AM\, Consultant Global Clinical Trials\n\nFOCUSES ON:\n\n\nMarket analysi s – Pharmacovigilance in 2022 - future horizons and efficiencies\nImpacts of PV on Covid-19\nRegulations\, Legal Implications for the pharmacovigi lance Industry\nOutsourcing in Pharmacovigilance- Best Practices\, Challe nges and key consideration\nNew Technologies in Pharmacovigilance (AI/ Ma chine Learning\, IoT\, Blockchain &\; Big Data)\nPV Audit &\; Inspe ctions – Knowing what is to be done\nNever let a crisis go to waste: Prac ticing Pharmacovigilance Post-Pandemic!\nRWE &\; RWD\nPV – Risk Manage ment and Planning - REMS\nDocumentation (RMPs\, PSURs\, PADERs\, PBRERs)\ nQuality\, Safety and Signal Detection - Future of 2020\nMedical devices – Increasing safety perspective\nCase studies from various countries on t he PV frameworks around the world\nPatient centric approach to help impro ve patient safety\nThe developing regulatory framework in advanced and de veloping markets – EU\, USA &\; ROW\nBe part of a major networking opp ortunity\n\nWHO SHOULD ATTEND:\n\nCEO’s\, CTO’s\, CIO’s\, Presidents\, VP s\, Directors\, Heads\, Managers\, Scientific Advisors\, Consultants of:\ n\nPharmacovigilance\, Pharmacoepidemiology\, Pharmacogenomics\, Drug/Pro duct Safety\, Drug Development\, Information and Clinical Data Management \, Clinical Pharmacology\, Clinical Safety\, Periodical safety update Rep orts\, Risk Management\, Research &\; Development\, Quality Assurance\ , Patient Safety\, Signal Detection\, Safety Surveillance\, Outcomes Rese arch\, Data Analysis\, Epidemiology\, Medical Affairs\, Regulatory Affair s and Compliance\, Information technology\, Sales and Marketing\n\nGet mo re from the event\, with a broader scope bringing the whole communication s value chain together. Enjoy and make the best out of our dedicated netw orking time\, meet the leading international vendors showcasing the produ cts of tomorrow in the virtual exhibition area. Expand your knowledge of the latest business models and strategies in the high-level conference.\n \n \;\n\n \;\n DTEND:20210923T170000 DTSTAMP:20260512T214301Z DTSTART:20210922T090000 LOCATION:\, SEQUENCE:0 SUMMARY:25th Pharmacovigilance 2021 \n“Latest developments in pharmacovigi lance\, drug safety &\; risk management”\n22nd - 23rd September 2021\, Virtual Co... UID:7e175746-d88d-4aaa-ae50-66040714b4d1 END:VEVENT END:VCALENDAR